5 research outputs found
Myocardial fibrosis in asymptomatic and symptomatic chronic severe primary mitral regurgitation and relationship to tissue characterisation and left ventricular function on cardiovascular magnetic resonance
Background: Myocardial fbrosis occurs in end-stage heart failure secondary to mitral regurgitation (MR), but it is not
known whether this is present before onset of symptoms or myocardial dysfunction. This study aimed to characterise
myocardial fbrosis in chronic severe primary MR on histology, compare this to tissue characterisation on cardiovascular magnetic resonance (CMR) imaging, and investigate associations with symptoms, left ventricular (LV) function, and
exercise capacity.
Methods: Patients with class I or IIa indications for surgery underwent CMR and cardiopulmonary exercise testing. LV
biopsies were taken at surgery and the extent of fbrosis was quantifed on histology using collagen volume fraction
(CVFmean) compared to autopsy controls without cardiac pathology.
Results: 120 consecutive patients (64±13 years; 71% male) were recruited; 105 patients underwent MV repair
while 15 chose conservative management. LV biopsies were obtained in 86 patients (234 biopsy samples in total).
MR patients had more fbrosis compared to 8 autopsy controls (median: 14.6% [interquartile range 7.4â20.3] vs. 3.3%
[2.6â6.1], P<0.001); this diference persisted in the asymptomatic patients (CVFmean 13.6% [6.3â18.8], P<0.001), but
severity of fbrosis was not signifcantly higher in NYHA II-III symptomatic MR (CVFmean 15.7% [9.9â23.1] (P=0.083).
Fibrosis was patchy across biopsy sites (intraclass correlation 0.23, 95% CI 0.08â0.39, P=0.001). No signifcant relationships were identifed between CVFmean and CMR tissue characterisation [native T1, extracellular volume (ECV)
or late gadolinium enhancement] or measures of LV function [LV ejection fraction (LVEF), global longitudinal strain
(GLS)]. Although the range of ECV was small (27.3±3.2%), ECV correlated with multiple measures of LV function (LVEF:
Rho=â0.22, P=0.029, GLS: Rho=0.29, P=0.003), as well as NTproBNP (Rho=0.54, P<0.001) and exercise capacity
(%PredVO2max: R=â0.22, P=0.030). Conclusions: Patients with chronic primary MR have increased fbrosis before the onset of symptoms. Due to the
patchy nature of fbrosis, CMR derived ECV may be a better marker of global myocardial status.
Clinical trial registration Mitral FINDER study; Clinical Trials NCT02355418, Registered 4 February 2015, https://clinicaltr
ials.gov/ct2/show/NCT0235541
Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: A systematic review and meta-analysis
Background: Hypertension and proteinuria are critically involved in the progression of chronic kidney disease. Despite treatment with renin angiotensin system inhibition, kidney function declines in many patients. Aldosterone excess is a risk factor for progression of kidney disease. Hyperkalaemia is a concern with the use of mineralocorticoid receptor antagonists. We aimed to determine whether the renal protective benefits of mineralocorticoid antagonists outweigh the risk of hyperkalaemia associated with this treatment in patients with chronic kidney disease. Methods: We conducted a meta-analysis investigating renoprotective effects and risk of hyperkalaemia in trials of mineralocorticoid receptor antagonists in chronic kidney disease. Trials were identified from MEDLINE (1966-2014), EMBASE (1947-2014) and the Cochrane Clinical Trials Database. Unpublished summary data were obtained from investigators. We included randomised controlled trials, and the first period of randomised cross over trials lasting â„4 weeks in adults. Results: Nineteen trials (21 study groups, 1 646 patients) were included. In random effects meta-analysis, addition of mineralocorticoid receptor antagonists to renin angiotensin system inhibition resulted in a reduction from baseline in systolic blood pressure (-5.7 [-9.0, -2.3] mmHg), diastolic blood pressure (-1.7 [-3.4, -0.1] mmHg) and glomerular filtration rate (-3.2 [-5.4, -1.0] mL/min/1.73 m2). Mineralocorticoid receptor antagonism reduced weighted mean protein/albumin excretion by 38.7 % but with a threefold higher relative risk of withdrawing from the trial due to hyperkalaemia (3.21, [1.19, 8.71]). Death, cardiovascular events and hard renal end points were not reported in sufficient numbers to analyse. Conclusions: Mineralocorticoid receptor antagonism reduces blood pressure and urinary protein/albumin excretion with a quantifiable risk of hyperkalaemia above predefined study upper limit
Myocardial fibrosis in asymptomatic and symptomatic chronic severe primary mitral regurgitation and relationship to tissue characterisation and left ventricular function on cardiovascular magnetic resonance
Background: Myocardial fbrosis occurs in end-stage heart failure secondary to mitral regurgitation (MR), but it is not
known whether this is present before onset of symptoms or myocardial dysfunction. This study aimed to characterise
myocardial fbrosis in chronic severe primary MR on histology, compare this to tissue characterisation on cardiovascular magnetic resonance (CMR) imaging, and investigate associations with symptoms, left ventricular (LV) function, and
exercise capacity.
Methods: Patients with class I or IIa indications for surgery underwent CMR and cardiopulmonary exercise testing. LV
biopsies were taken at surgery and the extent of fbrosis was quantifed on histology using collagen volume fraction
(CVFmean) compared to autopsy controls without cardiac pathology.
Results: 120 consecutive patients (64±13 years; 71% male) were recruited; 105 patients underwent MV repair
while 15 chose conservative management. LV biopsies were obtained in 86 patients (234 biopsy samples in total).
MR patients had more fbrosis compared to 8 autopsy controls (median: 14.6% [interquartile range 7.4â20.3] vs. 3.3%
[2.6â6.1], P<0.001); this diference persisted in the asymptomatic patients (CVFmean 13.6% [6.3â18.8], P<0.001), but
severity of fbrosis was not signifcantly higher in NYHA II-III symptomatic MR (CVFmean 15.7% [9.9â23.1] (P=0.083).
Fibrosis was patchy across biopsy sites (intraclass correlation 0.23, 95% CI 0.08â0.39, P=0.001). No signifcant relationships were identifed between CVFmean and CMR tissue characterisation [native T1, extracellular volume (ECV)
or late gadolinium enhancement] or measures of LV function [LV ejection fraction (LVEF), global longitudinal strain
(GLS)]. Although the range of ECV was small (27.3±3.2%), ECV correlated with multiple measures of LV function (LVEF:
Rho=â0.22, P=0.029, GLS: Rho=0.29, P=0.003), as well as NTproBNP (Rho=0.54, P<0.001) and exercise capacity
(%PredVO2max: R=â0.22, P=0.030). Conclusions: Patients with chronic primary MR have increased fbrosis before the onset of symptoms. Due to the
patchy nature of fbrosis, CMR derived ECV may be a better marker of global myocardial status.
Clinical trial registration Mitral FINDER study; Clinical Trials NCT02355418, Registered 4 February 2015, https://clinicaltr
ials.gov/ct2/show/NCT0235541
Safety of hospital discharge before return of bowel function after elective colorectal surgery
Background: Ileus is common after colorectal surgery and is associated with an increased risk of postoperative complications. Identifying features of normal bowel recovery and the appropriateness for hospital discharge is challenging. This study explored the safety of hospital discharge before the return of bowel function. Methods: A prospective, multicentre cohort study was undertaken across an international collaborative network. Adult patients undergoing elective colorectal resection between January and April 2018 were included. The main outcome of interest was readmission to hospital within 30 days of surgery. The impact of discharge timing according to the return of bowel function was explored using multivariable regression analysis. Other outcomes were postoperative complications within 30 days of surgery, measured using the Clavien\u2013Dindo classification system. Results: A total of 3288 patients were included in the analysis, of whom 301 (9\ub72 per cent) were discharged before the return of bowel function. The median duration of hospital stay for patients discharged before and after return of bowel function was 5 (i.q.r. 4\u20137) and 7 (6\u20138) days respectively (P < 0\ub7001). There were no significant differences in rates of readmission between these groups (6\ub76 versus 8\ub70 per cent; P = 0\ub7499), and this remained the case after multivariable adjustment for baseline differences (odds ratio 0\ub790, 95 per cent c.i. 0\ub755 to 1\ub746; P = 0\ub7659). Rates of postoperative complications were also similar in those discharged before versus after return of bowel function (minor: 34\ub77 versus 39\ub75 per cent; major 3\ub73 versus 3\ub74 per cent; P = 0\ub7110). Conclusion: Discharge before return of bowel function after elective colorectal surgery appears to be safe in appropriately selected patients
Search for new resonances decaying to a or boson and a Higgs boson in the , , and channels with collisions at TeV with the ATLAS detector
See paper for full list of authors, 18 pages (plus author list + cover pages: 36 pages total), 13 figures, 1 table. Submitted to PLB. All figures including auxiliary figures are available at https://atlas.web.cern.ch/Atlas/GROUPS/PHYSICS/PAPERS/EXOT-2015-18/International audienceA search is presented for new resonances decaying to a or boson and a Higgs boson in the , , and channels in collisions at TeV with the ATLAS detector at the Large Hadron Collider using a total integrated luminosity of 3.2 fb. The search is conducted by looking for a localized excess in the / invariant or transverse mass distribution. No significant excess is observed, and the results are interpreted in terms of constraints on a simplified model based on a phenomenological Lagrangian of heavy vector triplets